Association of UBE3C Variants with Reduced Kidney Function in Patients with Diabetic Kidney Disease
Open Access
- 6 November 2020
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (4), 210
- https://doi.org/10.3390/jpm10040210
Abstract
Diabetic kidney disease (DKD) is the leading cause of morbidity and mortality in patients with diabetes mellitus (DM) and the most common variant of end-stage renal disease (ESRD) globally. The economic burden of ESRD treatment with dialysis is substantial. The incidence and prevalence of ESRD in Taiwan remain the highest worldwide. Therefore, identifying genetic factors affecting kidney function would have valuable clinical implications. We performed microarray experiments and identified that ubiquitin protein ligase E3C (UBE3C) is differentially expressed in two DKD patient groups with extreme (low and high) urine protein-to-creatinine ratios. A follow-up genotyping study was performed in a larger group to investigate any specific variants of UBE3C associated with DKD. A total of 263 patients were included in the study, comprising 172 patients with DKD and 91 control subjects (patients with DM without chronic kidney disease (CKD)). Two UBE3C variants (rs3802129(AA) and rs7807(CC)) were determined to be associated with reduced kidney function. The haplotype analysis revealed that rs3802129/rs3815217 (block 1) with A/G haplotype and rs8101/rs7807 (block 2) with T/C haplotype were associated with higher risks of CKD phenotypes. These findings suggest a clinical role of UBE3C variants in DKD risk.This publication has 40 references indexed in Scilit:
- Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019Diabetes Care, 2019
- Diabetes and CKD in the United States Population, 2009–2014Clinical Journal of the American Society of Nephrology, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) stagingBMC Research Notes, 2014
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular OutcomesThe New England Journal of Medicine, 2011
- Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insuranceNephrology Dialysis Transplantation, 2008
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesThe New England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001